Search Results 2411-2420 of 13403 for monoclonal antibody
... antibodies to the virus, and essentially had no remaining treatment options. Oncolytic virotherapy – using re-engineered viruses to fight cancer – has a ...
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...
... antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase ...
Positive for human immunodeficiency virus (HIV) or hepatitis C antibody. Positive for hepatitis B surface antigen. Splenectomy within 3 months of screening ...
Positive test for HIV or hepatitis C antibodies. Positive test for HBsAg or HBcAb (a subject whose HBsAg is negative and HBcAb is positive may be enrolled ...
Clinically significant hepatitis at Screening, or hepatitis C antibody positive, hepatitis B surface antigen positive, or human immunodeficiency virus (HIV) ...
And it also has mutations that may make your antibodies, which are generated in response to vaccination, less able to bind or neutralize the virus. Once ...
ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can ...
Antibody-drug conjugates are targeted cancer therapies. They deliver potent drugs directly into cancer cells while minimizing harm to healthy tissue. These ...
The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.